Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571

British Journal of Haematology

Volumn 119, Issue 1, 2002, Pages 109-111

  Barthe, Christophe ^a   Gharbi, Marie Josée ^a   Lagarde, Valérie ^a   Chollet, Claudine ^a   Cony Makhoul, Pascale ^a   Reiffers, Josy ^a   Goldman, John M ^b   Melo, Junia V ^b   Mahon, François Xavier ^a,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c CNRS Bordeaux Segalen University   (France)

Author keywords

Chronic myeloid leukaemia; Drug resistance; Kinase domain mutation; STI571

Indexed keywords

ADENOSINE TRIPHOSPHATE; BCR ABL PROTEIN; GAMMA INTERFERON; GLUTAMIC ACID; IDARUBICIN; IMATINIB; LOMUSTINE; LYSINE; MERCAPTOPURINE; PROTEIN TYROSINE KINASE;

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BINDING SITE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CORRELATION FUNCTION; DISEASE COURSE; GENE MUTATION; HEMATOLOGY; HUMAN; HUMAN CELL; LABORATORY TEST; MALE; PATHOLOGY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; REMISSION; STEM CELL TRANSPLANTATION;

ADENOSINE TRIPHOSPHATE; ADULT; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; PIPERAZINES; POINT MUTATION; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 0036398414     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03708.x     Document Type: Article

References (10)

1. von Bubnoff, N., Schneller, F., Peschel, C. & Duyster, J. (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-positive leukaemia to STI571. Lancet, 359, 487-491.
2. Deininger, M.W., Goldman, J.M., Lydon, N. & Melo, J.V. (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood, 90, 3691-3698.
3. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., Capdeville, R. & Talpaz, M. (2001a) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine, 344, 1038-1042.
4. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S. & Sawyers, C.L. (2001b) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344, 1031-1037.
5. Gambacorti-Passerini, C., Barni, R., le Coutre, P., Zucchetti, M., Cabrita, G., Cleris, L., Rossi, F., Gianazza, E., Brueggen, J., Cozens, R., Pioltelli, P., Pogliani, E., Corneo, G., Formelli, F. & D'Incalci, M. (2000) Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL (+) leukemic cells to the abl inhibitor STI571. Journal of the National Cancer Institute, 92, 1641-1650.
6. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N. & Sawyers, C.L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293, 876-880.
7. Hochhaus, A., Kreil, S., Corbin, A., La Rosee, P., Lahaye, T., Berger, U., Cross, N.C., Linkesch, W., Druker, B.J., Hehlmann, R., Passerini, C., Corneo, G. & D'Incalci, M. (2001) Roots of clinical resistance to STI-571 cancer therapy. Science, 293, 2163.
8. Mahon, F.X., Deininger, M.W., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J.M. & Melo, J.V. (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood, 96, 1070-1079.
9. Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B. & Kuriyan, J. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science, 289, 1938-1942.
10. Weisberg, E. & Griffin, J.D. (2000) Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood, 95, 3498-3505.